NOW-HEALTH-INTERNATIONAL
7.6.2021 10:02:06 CEST | Business Wire | Press release
Now Health International Group, a leading International Private Medical Insurance (IPMI) provider, has announced a new program with Starr Insurance Companies, a leading global insurance company, to drive forward ambitious growth plans in Europe.
This mutually beneficial relationship combines Now Health International’s global presence and expertise in providing high quality international health insurance solutions and state of the art digital tools, including the recently launched Mobile Pass innovation, with Starr’s long-standing global knowledge and ability to deliver customised solutions across Europe through a specialised team of professionals dedicated to offering the best service to its customers.
Under the new agreement, as of 1st March 2021, Starr Insurance Companies will insure all new and renewing business across Europe. Now Health International will continue to administer the international health insurance plans, including claims handling and customer service support. All members will also continue to benefit from access to Now Health International’s award-winning digital tools.
Zahir Sharif, Managing Director, Now Health International said, “At Now Health International we are committed to further building our presence in Europe and have ambitions to expand into new markets across the region. Starr Insurance Companies, with over 100-years of heritage, expertise and existing presence across global markets, is a well-placed partner to help us achieve this goal.”
Now Health International will continue to offer its existing products to members across Europe under the new partnership, including its flagship, benefit-rich WorldCare product, and its more affordable SimpleCare product for those looking for essential health cover. There will be no changes to plan benefits, pricing, or the customer service experience as a result of this arrangement.
The new program replaces Now Health International’s previous relationship with AXA PPP Healthcare. To ensure a smooth transition process for existing members, a runoff period will be deployed until 31st December 2021, seamlessly transitioning members to the new arrangement with Starr Insurance Companies at their next plan renewal.
Michel Faucher, Chief Commercial Officer, Now Health International added, “We are very excited about our new relationship and the opportunities it presents for us in the long term. I also want to reassure our members and partners that there will be complete continuity under the new arrangements, with the same market-leading plans and benefits, high standards of service, and state of the art digital tools our European customer base have come to expect.”
Santiago Mora, Head of International Accident & Health for Starr, said, “We’re excited to be the insurance provider for Now Health International, one of the fastest growing providers of medical insurance solutions for global expatriates.”
-ENDS-
Notes to Editors: About Now Health International Group
The Now Health International Group consists of Now Health International and Best Doctors Insurance. Now Health International is one of the fastest growing providers of International Private Medical Insurance (IPMI) solutions for Global Expatriates, High-Net-Worth individuals and Companies. Now Health has offices in the UK, Malta, UAE, China, Hong Kong, Singapore and Indonesia. Best Doctors Insurance is a Bermuda/ Miami based major medical insurance provider with offices in the US, Canada and Ecuador and distribution throughout Central and Latin America, the Caribbean and Canada.
The combined business is a global top tier specialist IPMI provider, with complementary products, distribution and geographies. The operation spans four continents, with 11 sales &/or service offices, 125,000+ members, 370+ employees and 5,000+ distribution partners.
Notes to Editors: About Starr Insurance Companies
Starr Insurance Companies (or Starr) is a marketing name for the operating insurance and travel assistance companies and subsidiaries of Starr International Company, Inc. and for the investment business of C. V. Starr & Co., Inc. and its subsidiaries. Starr is a leading insurance and investment organization with a presence on six continents; through its operating insurance companies, Starr provides property, casualty, and accident and health insurance products as well as a range of specialty coverages including aviation, marine, energy and excess casualty insurance. Starr’s insurance company subsidiaries domiciled in the U.S., Bermuda, China, Hong Kong, Singapore, U.K. and Malta each have an A.M. Best rating of “A” (Excellent). Starr’s Lloyd’s syndicate has a Standard & Poor’s rating of “A+” (Strong).
View source version on businesswire.com: https://www.businesswire.com/news/home/20210607005024/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
